Acute Myeloblastic Leukemia Clinical Trial
Official title:
Partial Selective Depletion in Lymphocytes Transplant T CD4+ CCR7+ in Hematopoeitic Stem Cells Allograft
This is a preclinical study prior to the establishment of a cell therapy protocol applicable
to humans.
The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by
partial selective depletion of CD4 + CCR7 + graft to less than 50 % of CD4 + totals. To test
the alloreactivity of donor T lymphocytes.
This is a preclinical study prior to the establishment of a cell therapy protocol applicable
to humans.
The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by
partial selective depletion of CD4 + CCR7 + graft to less than 50 % of CD4 + totals. To test
the alloreactivity of donor T lymphocytes , T lymphocytes CD4 + CCR7 + donor will be
stimulated by mature dendritic cells (DC) derived from recipient circulating monocytes in a
mixed lymphocyte reaction model sensitized ( MLDCR ) , experiencing HLA -compatibility . This
first step will confirm the results previously obtained in a situation incompatible HLA .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04452604 -
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
|
||
| Completed |
NCT01041040 -
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
|
Phase 4 | |
| Completed |
NCT00552825 -
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
|
N/A | |
| Recruiting |
NCT01966497 -
Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia
|
N/A | |
| Active, not recruiting |
NCT01457885 -
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
|
Phase 2 | |
| Completed |
NCT04082286 -
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
|
Phase 1 | |
| Completed |
NCT01611116 -
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
|
Phase 2 | |
| Completed |
NCT00504920 -
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
|
N/A | |
| Completed |
NCT00354120 -
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
|
Phase 2/Phase 3 | |
| Completed |
NCT01435343 -
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT00487448 -
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
|
Phase 4 | |
| Recruiting |
NCT05499611 -
Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia
|
||
| Completed |
NCT00390715 -
Treatment of Acute Myeloblastic Leukemia in Younger Patients
|
Phase 4 | |
| Completed |
NCT05696457 -
Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT
|
N/A | |
| Recruiting |
NCT01296178 -
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
|
N/A | |
| Active, not recruiting |
NCT01307241 -
RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
|
N/A | |
| Completed |
NCT00435864 -
Natural Killer Index From Hematopoietic Stem Cell Graft
|
N/A |